Harrow Health, INC.: directors' dealings · United States · SEC (Form 4)

About Harrow Health, INC.

HARROW, INC. is a U.S.-based ophthalmology-focused pharmaceutical company listed on the NASDAQ (formerly Harrow Health, Inc.). Its corporate headquarters are in Nashville, Tennessee, United States. For investors, Harrow is best understood as a specialized eyecare platform rather than a broad-based pharmaceutical company: it develops, markets, and commercializes ophthalmic disease-management solutions across North America. The company was founded in December 2011 and has grown from a business with no products and no customers into an integrated ophthalmic pharmaceutical player. ([harrow.com](https://www.harrow.com/about/)) Harrow’s business model combines branded prescription products, ophthalmic compounding, and selective licensing/commercial agreements. Its core portfolio includes VEVYE, IHEEZO, IOPIDINE, ILEVRO, VIGAMOX, and TRIESENCE. VEVYE is an ophthalmic cyclosporine product used in dry eye disease, while IHEEZO is a topical ocular anesthetic administered under direct healthcare-provider supervision. TRIESENCE is notable because Harrow acquired rights to the product and relaunched it after it had been on the FDA shortage list for years, underscoring the company’s ability to restore supply on clinically important ophthalmic therapies. ImprimisRx, its ophthalmic compounding subsidiary, remains an important part of the platform and reflects the company’s origins in specialized eye-care formulations. ([investors.harrow.com](https://investors.harrow.com/products)) From a competitive standpoint, Harrow positions itself as a leading provider of ophthalmic disease management solutions in North America. Its differentiation comes from a focused product mix, relationships with eyecare professionals, and the ability to address multiple points in the treatment pathway. That said, the company operates in a highly competitive environment that includes branded drug manufacturers, generic alternatives, outsourcing facilities, and compounding pharmacies. Harrow’s strategic message emphasizes accessibility, affordability, and clinical utility—an important angle in the U.S. healthcare system, where pricing, reimbursement, and patient access can materially influence adoption. ([harrow.com](https://www.harrow.com/about/)) Geographically, Harrow’s commercial footprint is primarily in the United States, with a North American focus and selected Canadian rights for certain products. Recent developments have been centered on commercial scaling and portfolio expansion: management highlighted growth in VEVYE, expansion of IHEEZO into the office-based setting, and the relaunch of TRIESENCE. In its latest disclosures and earnings commentary, Harrow also reaffirmed its 2025 revenue guidance and then reported full-year 2025 results while outlining 2026 priorities, including continued sales-force expansion and development pipeline progress. For a French-, Belgian-, or Swiss-based investor, Harrow is a niche healthcare growth story on the NASDAQ, with a concentrated ophthalmology franchise and a recent record of operational execution. ([harrow.com](https://www.harrow.com/news-releases/news-release-details/harrow-announces-q4-and-full-year-2025-financial-results-and/))